Cassava Sciences reported $14.09M in Operating Expenses for its fiscal quarter ending in June of 2025.


Operating Expenses Change Date
Abbott USD 9.07B 369M Jun/2025
Amgen USD 6.52B 337M Jun/2025
Biogen USD 1.79B 326.1M Jun/2025
Cassava Sciences USD 14.09M 15.4M Jun/2025
Eisai JPY 181.91B 7.35B Jun/2025
Eli Lilly USD 8.54B 1.22B Jun/2025
Geron USD 61.49M 5.18M Jun/2025
J&J USD 16.8B 8.54B Jun/2025
Merck USD 9.44B 217M Jun/2025
Novartis USD 9.97B 1.02B Jun/2025
Pfizer USD 11.62B 1.58B Jun/2025
Roche Holding CHF 11.43B 1.48B Dec/2024